Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Neurogene Inc. (NGNE)

Capricor Therapeutics, Inc. and Neurogene Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. is the larger, with a market value of $572.7M against $520.3M — 1.1× the size. Across the 10 metrics below, Neurogene Inc. leads on 7 and Capricor Therapeutics, Inc. on 3.

Valuation

Metric CAPR NGNE Biotechnology median
P/E n/m n/m 10.85
P/S 25.75 n/m 9.49
P/B 2.33 2.69 2.18
Price to free cash flow 4.38 n/m 25.85
EV/EBITDA n/m n/m 0.70
EV/Sales 15.70 n/m 8.99
Earnings yield (24.75%) (19.40%) (31.76%)
Free cash flow yield 22.83% (15.00%) (21.84%)

Profitability

Metric CAPR NGNE Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (73.70%) (45.32%) (50.82%)
Return on assets (51.53%) (41.02%) (46.04%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR NGNE Biotechnology median
Revenue growth (TTM) (11.55%) — 6.96%
EPS growth (last fiscal year) (96.52%) 0.93% 29.88%
Revenue growth, 5-year CAGR 85.83% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR NGNE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 10.64 4.84
Net debt to EBITDA 2.99 2.57 1.01

Dividend

Metric CAPR NGNE Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric CAPR NGNE Biotechnology median
Market cap 572.67m 520.30m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack